JPRN-UMIN000002843招募中未知
The efficacy and safety of tocilizumab (trade name: Actemra) in RA patients. - The efficacy and safety of tocilizumab (trade name: Actemra) in RA patients.
Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2010年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with a history of sensitivity to any of the ingredients of Actemra 2)Patients with a serious concomitant infection 3)Patients with active tuberculosis 4)Patients with a lymphocyte count less than 500/ mcL 5)Patients with HCV, HBV or HIV infections 6)Other patients whom the investigator considers to be unsuitable for the study
研究者
相似试验
已完成
不适用
Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000007845Department of Cardiovascular Medicine Graduate School of Medicine Osaka University15
招募中
2 期
Evaluation the Efficacy and Safety of Tocilizumab in COVID-19COVID-19 pneumonia.Confirmed diagnosis of COVID-19RA01.0IRCT20151227025726N13Shahid Beheshti University of Medical Sciences40
已完成
不适用
The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Studyneuromyelitis opticaJPRN-UMIN000007866Department of Immunology, National Institute of Neuroscience, NCNP15
已完成
不适用
The safety and efficacy of tocilizumab in patients with neuromyelitis opticaneuromyelitis opticaJPRN-UMIN000005889Department of Immunology, National Institute of Neuroscience, NCNP3
已完成
不适用
The efficacy and safety of tocilizumab in patients with neuromyelitis opticaneuromyelitis opticaJPRN-UMIN000022201Department of Neurology, Shimane University Hospital3